Related Experiment Video
Updated: Aug 23, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Novel therapies for pancreatic adenocarcinoma
Simona M Pino1, Henry Q Xiong, David McConkey
1Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Abstract:
Despite advances in our understanding of the molecular and genetic basis of pancreatic cancer, the disease remains a clinical challenge. Gemcitabine, the standard chemotherapy for pancreatic cancer, offers modest improvement of tumor-related symptoms and marginal advantage of survival. New approaches, alone and in combination with gemcitabine, are being developed to combat this cancer. In this article we review the current status of investigations into several classes of agents: matrix metalloproteinase inhibitors; farnesyl transferase inhibitors; epidermal growth factor receptor inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors; cyclooxygenase-2 inhibitors, and others. The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed.
Insights
Pancreatic cancer remains challenging despite advances. This review explores novel therapeutic agents, including matrix metalloproteinase inhibitors and epidermal growth factor receptor inhibitors, to improve treatment outcomes beyond standard gemcitabine chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Pancreatic cancer presents significant clinical challenges despite progress in molecular and genetic understanding.
- Gemcitabine, the current standard chemotherapy, provides limited benefits in symptom management and survival for pancreatic cancer patients.
Purpose of the Study:
- To review the current investigational status of novel therapeutic agents for pancreatic cancer.
- To discuss the scientific rationale, mechanisms of action, and clinical trial data for emerging treatments.
Main Methods:
- Literature review of preclinical and clinical investigations.
- Analysis of data from clinical trials involving novel agents.
- Discussion of drug classes including matrix metalloproteinase inhibitors, farnesyl transferase inhibitors, epidermal growth factor receptor inhibitors, and cyclooxygenase-2 inhibitors.
Main Results:
- Several novel classes of agents are under investigation for pancreatic cancer treatment.
- These agents target various molecular pathways implicated in cancer progression.
- Early clinical data and scientific rationale for these novel therapies are presented.
Conclusions:
- Novel therapeutic strategies are crucial to overcome the limitations of current pancreatic cancer treatments.
- Targeted therapies and combination approaches hold promise for improving patient outcomes.
- Continued research into these agents is essential for advancing pancreatic cancer care.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...